AbbVie: CHMP Recommends Approval of Shorter Maviret Duration
January 31 2020 - 7:05AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. (ABBV) on Friday said the European Medicines
Agency's Committee for Medicinal Products for Human Use recommended
approval of a shorter Maviret treatment duration in certain
patients with chronic hepatitis C.
The North Chicago, Ill., biopharmaceutical company said the
CHMP's positive opinion covers shortening the once-daily treatment
duration to eight weeks from 12 in treatment-naive, compensated
cirrhotic, chronic hepatitis C patients with genotype 3
infection.
AbbVie said the change, if approved by the European Commission,
will make Maviret the only pan-genotypic eight-week treatment
option for treatment-naive chronic hepatitis C patients, without
cirrhosis or with compensated cirrhosis.
The EC, which generally follows the CHMP's recommendations, is
expected make a decision this year, AbbVie said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 31, 2020 07:50 ET (12:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024